Qiagen (NYSE:QGEN) Given Consensus Rating of “Moderate Buy” by Analysts

Qiagen (NYSE:QGEN) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $51.88.

QGEN has been the subject of a number of research analyst reports. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th.

Institutional Trading of Qiagen

A number of hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after purchasing an additional 500 shares during the period. Toronto Dominion Bank purchased a new stake in Qiagen in the 2nd quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Qiagen during the 3rd quarter valued at $53,000. Finally, CWM LLC increased its stake in shares of Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after acquiring an additional 269 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Trading Up 0.6 %

Shares of Qiagen stock opened at $44.32 on Friday. The business has a fifty day simple moving average of $43.28 and a 200-day simple moving average of $43.76. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The firm has a market cap of $10.11 billion, a price-to-earnings ratio of 113.64, a price-to-earnings-growth ratio of 3.52 and a beta of 0.35. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.